Corvus Pharmaceuticals, Inc. Increase Decrease In Operating Lease Liability
Corvus Pharmaceuticals, Inc. (CRVS) reported Increase Decrease In Operating Lease Liability of -$209.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$106.00K.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$103.00K, a 432.26% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$74.00K, a 109.64% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$72.00K.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2025 was -$185.00K.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2024 was -$252.00K.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.23M.
- Corvus Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2022 was -$1.05M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$209.00K 10-Q · filed 2026-08-06 | -$283.00K derived: sum of 3 quarters · filed 2026-08-06 | -$355.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$103.00K 10-Q · filed 2026-05-07 | -$177.00K derived: sum of 2 quarters · filed 2026-05-07 | -$249.00K derived: sum of 3 quarters · filed 2026-05-07 | -$319.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$146.00K derived: sum of 2 quarters · filed 2026-03-12 | -$216.00K derived: sum of 3 quarters · filed 2026-08-06 | -$185.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$142.00K derived: sum of 2 quarters · filed 2026-08-06 | -$111.00K 10-Q · filed 2025-11-04 | $657.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$39.00K 10-Q · filed 2026-08-06 | $729.00K derived: sum of 3 quarters · filed 2026-08-06 | $383.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $31.00K 10-Q · filed 2026-05-07 | $799.00K derived: sum of 2 quarters · filed 2026-05-07 | $453.00K derived: sum of 3 quarters · filed 2026-05-07 | $113.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $768.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $422.00K derived: sum of 2 quarters · filed 2026-03-12 | $82.00K derived: sum of 3 quarters · filed 2026-03-12 | -$252.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$346.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$686.00K derived: sum of 2 quarters · filed 2025-11-04 | -$1.02M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$674.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$334.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$1.23M 10-K · filed 2026-03-12 | |||
| 2022-12-31 | -$1.05M 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |